NYRx E&O Update
- Flovent® and Advair® products continue to be included in the NYRx Brand Less Than Generic Program (BLTG).
- Due to recent changes announced by the manufacturer including the discontinuation of Flovent® and the decreased production of Advair®, effective December 21, 2023, the NYRx Medicaid Pharmacy Program will allow for the generics to these products to adjudicate without prior authorization. Prescribers do not need to submit prior authorizations to NYRx for these generic products currently.
- When prescribing Brand name drugs included in the BLTG program, prescriptions do not require “Dispense as Written” (DAW) or “Brand Medically Necessary.”
- If a pharmacy is unable to obtain Flovent® or Advair® from their wholesaler and the member needs the medication, they may submit for the generic product.
For more information, refer to the latest program update (12/21/23) on the BLTG Program Updates Website: NYRx, the Medicaid Pharmacy Program | BLTGP (fhsc.com)
The NYRx Education and Outreach team serves as a liaison between the Managed Care Plans and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:
- Managed Care Plans
- Case workers and New York State agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies.
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C
To contact the NYRx Education and Outreach team:
- Email them at [email protected]
- Call (833) 967-7310. The call center is available Monday through Friday, 8am until 5 pm ET.
Visit the website: NYRx Education & Outreach
